Patents by Inventor Michel Sadelain

Michel Sadelain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS
    Publication number: 20220031754
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 3, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • Cells comprising non-HLA restricted T cell receptors
    Patent number: 11229669
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 25, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES
    Publication number: 20220016170
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: July 21, 2021
    Publication date: January 20, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Matthias Stephan
  • Cancer antigen targets and uses thereof
    Patent number: 11193938
    Abstract: The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: December 7, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Fabiana Perna
  • CHIMERIC ANTIGEN RECEPTOR TARGETING SIALYL LEWIS A AND USES THEREOF
    Publication number: 20210246221
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., pancreatic cancer). It relates to antigen recognizing receptor (e.g., chimeric antigen receptors (CARs)) that specifically target Sialyl Lewis A (e.g., human Sialyl Lewis A), and immunoresponsive cells comprising such CARs. The presently disclosed Sialyl Lewis A-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: April 19, 2021
    Publication date: August 12, 2021
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, BIONTECH RESEARCH AND DEVELOPMENT, INC.
    Inventors: Michel Sadelain, David J. Hansen
  • LOW DOSE RADIATION CONDITIONING FOR IMMUNOTHERAPY
    Publication number: 20210236554
    Abstract: The present disclosure provides methods and compositions for treating cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing a secretable TRAIL polypeptide.
    Type: Application
    Filed: April 19, 2021
    Publication date: August 5, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Carl DeSelm
  • Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
    Patent number: 11077140
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: August 3, 2021
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Matthias Stephan
  • METHODS AND COMPOSITIONS FOR TUMOR RADIOSENSITIZATION
    Publication number: 20210069330
    Abstract: Disclosed herein are methods and compositions for radiosensitizing tumor in subjects receiving radiation therapy by administering a gene therapy construct that results in expression of a secretory radiosensitizing agent in tumor endothelium.
    Type: Application
    Filed: August 27, 2020
    Publication date: March 11, 2021
    Inventors: Richard N. KOLESNICK, Branka STANCEVIC, Michel SADELAIN, Zvi FUKS, Nira VARDA-BLOOM, Dror HARATS
  • CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS
    Publication number: 20210030804
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • NON-HLA RESTRICTED T CELL RECEPTORS AND USES THEREOF
    Publication number: 20200368283
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 26, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • METHODS OF TREATMENTS USING ANTIGEN-BINDING PROTEINS TARGETING CD56
    Publication number: 20200325223
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
    Inventors: Michel Sadelain, Reuben Benjamin, Dimiter S. Dimitrov, Yang Feng
  • COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20200317781
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: April 13, 2020
    Publication date: October 8, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • ENHANCED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20200317777
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto
  • GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES
    Publication number: 20200291433
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Annalisa Cabriolu
  • METHODS AND COMPOSITIONS FOR ALLEVIATING CYTOKINE RELEASE SYNDROME
    Publication number: 20200268793
    Abstract: The present disclosure provides methods and compositions for treating cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing a secretable IL-1Ra polypeptide.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Theodoros Giavridis
  • Antigen-binding proteins targeting CD56 and uses thereof
    Patent number: 10730941
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 4, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Michel Sadelain, Reuben Benjamin, Dimiter S. Dimitrov, Yang Feng
  • USES OF MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20200239569
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: March 17, 2020
    Publication date: July 30, 2020
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • CANCER ANTIGEN TARGETS AND USES THEREOF
    Publication number: 20200182880
    Abstract: The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Fabiana Perna
  • Compositions and methods for immunotherapy
    Patent number: 10654928
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: May 19, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • Mesothelin-targeted chimeric antigen receptors and uses thereof
    Patent number: 10633441
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 28, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng